2,883
Views
17
CrossRef citations to date
0
Altmetric
Respiratory Medicine

Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants

, , , &
Pages 139-147 | Received 26 Jun 2019, Accepted 09 Aug 2019, Published online: 04 Sep 2019

References

  • Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–1928.
  • Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–1759.
  • Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality — United States, 2014–2017. MMWR Morb Mortal Wkly Rep. 2018;67:71–76.
  • Doucette A, Jiang X, Fryzek J, et al. Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997–2012. PLoS One. 2016;11:e0152208.
  • Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–598.
  • Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143:127–132.
  • Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865–870.
  • IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537.
  • Synagis (palivizumab) [prescribing information]. Gaithersburg (MD): AstraZeneca; 2014.
  • Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474–e1502.
  • Goldstein M, Krilov LR, Fergie J, et al. Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012–2016. Am J Perinatol. 2018;35:1433–1442.
  • Byington CL, Wilkes J, Korgenski K, et al. Respiratory syncytial virus–Associated mortality in hospitalized infants and young children. Pediatrics. 2015;135:e24.
  • McLaurin KK, Farr AM, Wade SW, et al. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. J Perinatol. 2016;36:990.
  • Carbonell-Estrany X, Pérez-Yarza EG, García LS, et al. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants—The SPRING study. PLoS One. 2015;10:e0125422.
  • Shefali-Patel D, Paris MA, Watson F, et al. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171:1055–1061.
  • Shi N, Palmer L, Chu B-C, et al. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. J Med Econ. 2011;14:335–340.
  • Roggeri DP, Roggeri A, Rossi E, et al. Impact of hospitalizations for bronchiolitis in preterm infants on long-term health care costs in Italy: a retrospective case-control study. CEOR. 2016;8:407–412.
  • IBM MarketScan Research Databases for health services researchers. In: IBM, editor. 2018. Available from: https://www.ibm.com/downloads/cas/6KNYVVQ2
  • Consumer Price Index details report tables annual average 2016: United States Department of Labor; 2017 [cited 2018 22 Jun 2018]. Available from: https://www.bls.gov/cpi/tables.htm